<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455754</url>
  </required_header>
  <id_info>
    <org_study_id>LYNEX</org_study_id>
    <nct_id>NCT00455754</nct_id>
  </id_info>
  <brief_title>Esomeprazole Treatment for Patients With Lymphocytic Gastritis</brief_title>
  <acronym>LYNEX</acronym>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on the Efficacy of Esomeprazole Treatment for Patients With Lymphocytic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with esomeprazole alone is able
      to heal patients with lymphocytic gastritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, a placebo controlled trial of our group has shown that H. pylori eradication
      therapy consisting of omeprazole 20 mg bid, clarithromycin 500 mg bid, amoxicillin 1000 mg
      bid for seven days leads to a complete long-lasting resolution of lymphocytic gastritis in 96
      % of patients. However, after 3 months we also found a healing rate of 50 % in patients who
      received omeprazole 20 mg bid and placebo antibiotics for seven days suggesting spontaneous
      remission or a potential PPI effect. Thus, we speculate that PPI therapy may have led to
      elimination of H. pylori and subsequently healing of lymphocytic gastritis in those patients
      with potentially minimal H. pylori colonization at baseline. For this reason we investigate
      whether a PPI treatment alone is able to heal patients with lymphocytic gastritis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to assess the healing rate of</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>patients with lymphocytic gastritis irrespective of H. pylori status after treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>with esomeprazole 20 mg twice daily for 2 weeks.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objective of the study are to evaluate the grade and activity of gastritis before and after</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment according to updated Sydney classification, to assess the clinical GI symptoms at baseline and after 3 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and to evaluate influence of the H. pylori-Status</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Lymphocytic Gastritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven lymphocytic gastritis (IEL &gt; 25/100)

          -  Male or female aged 18 years or older

          -  Signed and written informed consent

        Exclusion Criteria:

          -  Regular NSAID or aspirin intake

          -  Concomitant medication with antibiotics, bismuth subsalicylate, aminosalicylates

          -  Regular PPI therapy

          -  Treatment with ketoconazole or other CYP3A inhibitors

          -  previous surgery of the stomach

          -  known or suspected hypersensitivity to esomeprazole

          -  Malignant diseases

          -  Concomitant severe diseases

          -  Pregnancy or lactation

          -  Contraindication to take biopsies (Quick &lt; 50%, PTT &gt; 50 s, thrombocytes &lt;
             100.000/mm3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Madisch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Department I, University Hospital Carl Gustav Carus, Technical University Dresden, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Madisch, MD</last_name>
    <phone>++493514584780</phone>
    <email>ahmed.madisch@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Miehlke, Prof., MD</last_name>
    <phone>++493514585645</phone>
    <email>stephan.miehlke@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Department I, University Hospital Carl Gustav Carus, Technical University</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Madisch, MD</last_name>
      <phone>++493514584780</phone>
      <email>ahmed.madisch@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Miehlke, Prof.</last_name>
      <phone>++493514585645</phone>
      <email>stephan.miehlke@uniklinikum-dresden.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>April 3, 2007</last_update_submitted>
  <last_update_submitted_qc>April 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

